tradingkey.logo
tradingkey.logo
Search

Evolus Inc

EOLS
Add to Watchlist
6.500USD
-0.080-1.22%
Close 05/15, 16:00ETQuotes delayed by 15 min
428.06MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-1.22%

5 Days

+2.20%

1 Month

+43.49%

6 Months

-9.97%

Year to Date

-2.26%

1 Year

-32.99%

TradingKey Stock Score of Evolus Inc

Currency: USD Updated: 2026-05-15

Key Insights

Evolus Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 15 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.67.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Evolus Inc's Score

Industry at a Glance

Industry Ranking
15 / 155
Overall Ranking
54 / 4482
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Evolus Inc Highlights

StrengthsRisks
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 47.05% year-on-year.
Fairly Valued
The company’s latest PE is -9.73, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 50.03M shares, decreasing 24.26% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 7.50K shares of this stock.

Analyst Rating

Based on 7 analysts
Buy
Current Rating
14.667
Target Price
+122.90%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Evolus Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Evolus Inc Info

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Ticker SymbolEOLS
CompanyEvolus Inc
CEOMoatazedi (David)
Websitehttps://www.evolus.com/
KeyAI